Download full-text PDF

Source

Publication Analysis

Top Keywords

"my rings
4
rings fit
4
fit anymore"
4
anymore" ectopic
4
ectopic growth
4
growth hormone-secreting
4
hormone-secreting tumor
4
"my
1
fit
1
anymore"
1

Similar Publications

In this communication, the concept of metasurface absorber is utilized to enhance the isolation in the dual port multiple-input multiple-output (MIMO) antenna specially designed for a wideband millimeter wave operation. The frequency of operation of the designed module is 32.5-42.

View Article and Find Full Text PDF
Article Synopsis
  • The article introduces a compact and polarization-insensitive Metamaterial energy harvester that operates efficiently in both S-band and C-band frequencies, addressing limitations of current designs that are often large and single-band.
  • The harvester features a unique design with a rectangle strip and embedded hexagonal ring resonators, achieving impressive energy harvesting efficiencies of 97% at 3.5 GHz and 98% at 5.5 GHz.
  • Experimental results from a 3 × 3 array confirm the design's reliability and effectiveness, highlighting its potential for diverse energy harvesting applications due to its high efficiency and small size (10 × 10 mm).
View Article and Find Full Text PDF

Two novel diarylethene-fused subporphyrinoids were prepared and characterized. A mono diarylethene derivative was obtained via a statistical condensation reaction with 2 eq. of 1,2-dicyanobenzene and 1 eq.

View Article and Find Full Text PDF

Hugh Nakamura.

Angew Chem Int Ed Engl

October 2024

"My favorite molecule is tryptophan because it already has two rings and a chiral center… If I won a million dollars in the lottery I would hire ten postdocs…" Find out more about Hugh Nakamura in his Introducing… Profile.

View Article and Find Full Text PDF

The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate.

Clin Genitourin Cancer

October 2024

Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA; Department of Medical Oncology and Developmental Therapeutics, City of Hope Cancer Center, Goodyear, AZ, USA. Electronic address:

Article Synopsis
  • Lurbinectedin is FDA-approved for treating metastatic small cell lung cancer (SCLC), but there is no data on its use for small cell or neuroendocrine prostate cancer (SC/NEPC), which behaves similarly.
  • A study involving 18 SC/NEPC patients treated with lurbinectedin reported a clinical benefit rate of 56%, with common treatment-related adverse events including fatigue and anemia.
  • Results showed modest clinical benefits: median overall survival was about 6 months and progression-free survival was around 3.35 months, highlighting the need for further studies to confirm lurbinectedin's effectiveness as a treatment option for SC/NEPC.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!